ASCO 2024 | A multi-omic study to improve the diagnosis of multiple myeloma
Claudio Cerchione
• 23 May 2024
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses a multi-omic study of the biology of multiple myeloma to aid with diagnosis and optimizing treatment. The study combines diagnostic methods, including fludeoxyglucose-18 (FDG) positron emission tomography (PET) and full body magnetic resonance imaging (MRI), and hopes to contribute to the development of a new prognostic score. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
